Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology-Beaumont
mi
from
Beaumont, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology-Beaumont
mi
from
Beaumont, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology Texas Cancer Center at Medical City
mi
from
Dallas, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology Texas Cancer Center at Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Baylor Charles A Sammons Cancer Center
mi
from
Dallas, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Baylor Charles A Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology-Flower Mound
mi
from
Flower Mound, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology-Flower Mound
mi
from
Flower Mound, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology Southwest Forth Worth
mi
from
Fort Worth, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology Southwest Forth Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology, Fort Worth
mi
from
Ft. Worth, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology, Fort Worth
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology - Garland
mi
from
Garland, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology - Garland
mi
from
Garland, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Cancer Care Centers of South Texas-HOAST
mi
from
New Braunfels, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Cancer Care Centers of South Texas-HOAST
mi
from
New Braunfels, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology-Paris
mi
from
Paris, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology-Paris
mi
from
Paris, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology-Plano East
mi
from
Plano, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology-Plano East
mi
from
Plano, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Cancer Care Centers of South Texas-HOAST
mi
from
San Antonio, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Cancer Care Centers of South Texas-HOAST
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology-Tyler
mi
from
Tyler, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Onc and Hem Associates of SW VA, Inc. d/b/a Blue Ridge Cancer Care
mi
from
Christiansburg, VA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Onc and Hem Associates of SW VA, Inc. d/b/a Blue Ridge Cancer Care
mi
from
Christiansburg, VA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Onc and Hem Associates of SW VA, Inc.
mi
from
Christiansburg, VA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Onc and Hem Associates of SW VA, Inc.
mi
from
Christiansburg, VA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Virginia Oncology Associates
mi
from
Hampton, VA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Virginia Oncology Associates
mi
from
Hampton, VA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Virginia Oncology Associates
mi
from
Newport News, VA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Virginia Oncology Associates
mi
from
Newport News, VA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Onc and Hem Associates of SW VA, Inc. d/b/a Blue Ridge Cancer Care
mi
from
Roanoke, VA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Onc and Hem Associates of SW VA, Inc. d/b/a Blue Ridge Cancer Care
mi
from
Roanoke, VA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Onc and Hem Assoc of SW VA, Inc d/b/a Blue Ridge Cancer Care
mi
from
Salem, VA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Onc and Hem Assoc of SW VA, Inc d/b/a Blue Ridge Cancer Care
mi
from
Salem, VA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Onc and Hem Associates of SW VA, Inc. d/b/a Blue Ridge Cancer Care
mi
from
Wytheville, VA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Onc and Hem Associates of SW VA, Inc. d/b/a Blue Ridge Cancer Care
mi
from
Wytheville, VA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
University of Washington/Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
University of Washington/Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Cancer Care Northwest-Valley
mi
from
Spokane Valley, WA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Cancer Care Northwest-Valley
mi
from
Spokane Valley, WA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Cancer Care Northwest
mi
from
Spokane, WA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Cancer Care Northwest - North
mi
from
Spokane, WA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Cancer Care Northwest - North
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Northwest Cancer Specialists
mi
from
Vancouver, WA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Northwest Cancer Specialist
mi
from
Vancouver, WA
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Northwest Cancer Specialist
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated:  9/1/2015
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Status: Enrolling
Updated: 9/1/2015
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Stanford Cancer Center
mi
from
Stanford, CA
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Childrens National Medical Center
mi
from
Washington,
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Lee Cancer Care of Lee Memorial Health System
mi
from
Fort Myers, FL
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Lee Cancer Care of Lee Memorial Health System
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Nemours Children's Clinic
mi
from
Jacksonville, FL
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Sacred Heart Cancer Center at Sacred Heart Hospital
mi
from
Pensacola, FL
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Sacred Heart Cancer Center at Sacred Heart Hospital
mi
from
Pensacola, FL
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
All Children's Hospital
mi
from
St. Petersburg, FL
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
All Children's Hospital
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
St. Joseph's Cancer Institute at St. Joseph's Hospital
mi
from
Tampa, FL
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
St. Joseph's Cancer Institute at St. Joseph's Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
MBCCOP - Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
MBCCOP - Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Advocate Christ Medical Center
mi
from
Oak Lawn, IL
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Advocate Christ Medical Center
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Kosair Children's Hospital
mi
from
Louisville, KY
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Kosair Children's Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated:  9/1/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
Pharmacokinetics of Daunomycin in Children
Status: Enrolling
Updated: 9/1/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials